{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:53:36Z","timestamp":1795190016741,"version":"4.10.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine cut-off values of BASDAI that can discriminate the four disease activity states (inactive disease, moderate disease activity, high disease activity and very high disease activity), separated by the validated Ankylosing Spondylitis Disease Activity Score (ASDAS) cut-off values (1.3, 2.1 and 3.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included 333 patients with axial SpA whose data on BASDAI and ASDAS-CRP were available. Receiver operating characteristic curve analysis was performed to determine the BASDAI cut-off values that best corresponded to ASDAS-CRP cut-off values. The degree of agreement between disease activity states based on the BASDAI and ASDAS-CRP cut-off values was assessed using weighted kappa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the total 333 patients, 52 (15.6%), 190 (57.1%), 76 (22.8%) and 15 (4.5%) patients had inactive disease, moderate disease activity, high disease activity and very high disease activity, respectively, according to the ASDAS-CRP. Receiver operating characteristic analyses revealed that the BASDAI values 1.9 [area under the curve (AUC) 0.948; 95% CI 0.922, 0.974], 3.5 (AUC 0.926; 95% CI 0.887, 0.966) and 4.9 (AUC 0.917; 95% CI 0.837, 0.996) best corresponded to the ASDAS-CRP values 1.3, 2.1 and 3.5, respectively. The degree of agreement between disease activity states based on the BASDAI and ASDAS-CRP cut-off values was good (weighted kappa: 0.724, P &amp;lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The BASDAI values 1.9, 3.5 and 4.9 corresponded to the ASDAS-CRP values 1.3, 2.1 and 3.5, respectively. These cut-off values could be useful in clinical studies and real-world practice for determining disease activity status when ASDAS-CRP is unavailable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab494","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T11:53:58Z","timestamp":1632225238000},"page":"2369-2374","source":"Crossref","is-referenced-by-count":30,"title":["BASDAI cut-off values corresponding to ASDAS cut-off values"],"prefix":"10.1093","volume":"61","author":[{"given":"Oh Chan","family":"Kwon","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine , Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Chan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine , Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"2022060114032342600_keab494-B1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060114032342600_keab494-B2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022060114032342600_keab494-B3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022060114032342600_keab494-B4","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2022060114032342600_keab494-B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022060114032342600_keab494-B6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2022060114032342600_keab494-B7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Spondyloarthritis: is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2022060114032342600_keab494-B8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022060114032342600_keab494-B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022060114032342600_keab494-B10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","article-title":"Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients","volume":"80","author":"Godfrin-Valnet","year":"2013","journal-title":"Joint Bone Spine"},{"key":"2022060114032342600_keab494-B11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/acr.24266","article-title":"Measuring outcomes in axial spondyloarthritis","volume":"72(Suppl 10","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022060114032342600_keab494-B12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/keh595","article-title":"Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives","volume":"44","author":"Spoorenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2022060114032342600_keab494-B13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022060114032342600_keab494-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2022060114032342600_keab494-B15","first-page":"111","article-title":"Evidence based emergency medicine; part 5 receiver operating curve and area under the curve","volume":"4","author":"Safari","year":"2016","journal-title":"Emerg (Tehran)"},{"key":"2022060114032342600_keab494-B16","first-page":"146","article-title":"Validation of disease activity and functional status questionnaires in spondyloarthritis","volume":"33","author":"Quinzanos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022060114032342600_keab494-B17","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/1756-185X.13735","article-title":"Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore","volume":"22","author":"Kwan","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2022060114032342600_keab494-B18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/rheumatology\/kez480","article-title":"How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula","volume":"59","author":"Aranda-Valera","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022060114032342600_keab494-B19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/keaa241","article-title":"Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable","volume":"60","author":"Ortolan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022060114032342600_keab494-B20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbspin.2019.07.007","article-title":"Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis","volume":"87","author":"Proft","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2022060114032342600_keab494-B21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4078\/jrd.2020.27.1.4","article-title":"The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus","volume":"27","author":"Park","year":"2020","journal-title":"J Rheum Dis"},{"key":"2022060114032342600_keab494-B22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/rheumatology\/kes057","article-title":"Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria","volume":"51","author":"Fagerli","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2022060114032342600_keab494-B23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Reumatol Clin"},{"key":"2022060114032342600_keab494-B24","doi-asserted-by":"crossref","first-page":"e001145","DOI":"10.1136\/rmdopen-2019-001145","article-title":"Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI","volume":"6","author":"Marona","year":"2020","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab494\/40572143\/keab494.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2369\/43891599\/keab494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2369\/43891599\/keab494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T14:05:00Z","timestamp":1654092300000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2369\/6374903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,24]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab494","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,9,24]]}}}